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Abstract
Background/Aim. There is a lack of data on the effects
of prolactin on calcium metabolism and bone turnover in
hyperprolactinemia of various origins. The aim of this
study was to compare the influence of medicamentous and
physiological hyperprolactinemia on bone turnover in fe-
male rats. Methods. Experimental animals (18 weeks old,
Wistar female rats) were divided as follows: the group P –
9 rats, 3 weeks pregnant; the group M3–10 rats that were
intramuscularly administrated sulpirid (10 mg/kg) twice
daily for 3 weeks, the group M6 – 10 rats that were intra-
muscularly administrated with sulpirid (10 mg/kg) twice
daily for 6 weeks, and age matched nulliparous rats as the
control group: 10 rats, 18-week-old (C1) and 7 rats, 24
weeks old (C2). Laboratory investigations included serum
ionized calcium and phosphorus, urinary calcium and
phosphorous excretion, osteocalcin and serum procollagen
type 1 N-terminal propeptide (P1NP). Results.  Experi-
mental animals in the group P compared to the control
group, displayed lower mean serum ionized calcium
(0.5 ± 0.2 vs 1.12 ± 0.04 mmol/L; p < 0.001); higher mean
serum phosphorus (2.42  ±  0.46 vs  2.05 ± 0.2  mmol/L;
p  <  0.05); increased urinary calcium (3.90  ±  0.46 vs
3.05 ± 0.58;  p <  0.01) and significantly increased P1NP
(489,22 ± 46,77 vs 361.9 ± 53,01 pg/mL; p < 0.001). Ex-
perimental animals in the group M3 had significantly de-
creased P1NP, compared to the contol group. Prolongated
medicamentous hyperprolactinemia (the group M6) in-
duced increased serum ionized calcium (1.21  ±  0.03 vs
1.15 ± 0.02  mmol/L;  p  <  0.001); decreased serum phos-
phorus (1.70  ±  0.13 vs  1.89 ± 0.32  mmol/L;  p < 0.001);
decreased osteocalcin and P1NP. Conclusions.  Physio-
logical hyperprolactinemia does not have such harmful ef-
fect on bone metabolism as medicamentous hyperprolac-
tinemia. Chronic medicamentous hyperprolactinemia pro-
duces lower serum levels of bone formation markers. As-
sessment of bone turnover markers in prolongated
medicamentous hyperprolactinemia provides an opportu-
nity for earlier diagnosis of bone metabolism disturbances
and should be considered as mandatory.
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Apstrakt
Uvod/Cilj. Nema dovoljno podataka o efektima prolaktina
na metabolizam kalcijuma i koštani promet kod hiperprola-
ktinemije razliÿitog porekla. Cilj ovog rada bio je da uporedi
uticaj medikamentne i fiziološke hiperprolaktinemije na ko-
štani metabolizam kod ženki pacova. Metode.  Eksperi-
mentalne životinje (ženke pacova soja Wistar, stare 18 ne-
delja) podeljene su na sledeýe grupe: grupa P – devet pacova
u treýoj nedelji trudnoýe; grupa M3 – 10 pacova, kojima je
tokom tri nedelje, dva puta dnevno, davan intramuskularno
sulpirid (10 mg/kg); grupa M6 – 10 pacova kojima je tokom
šest nedelja, davan sulpirid (10 mg/kg) intramuskularno, dva
puta dnevno; starosno odgovarajuýe nulipare ženke pacova
kao kontrolne grupe: C1 – 10 pacova, starih 18 nedelja i C2
– sedam pacova, starih 24 nedelje. OdreĀivana je koncentra-
cija jonizovanog kalcijuma i fosfora u serumu, 24-ÿasovno
izluÿivanje kalcijuma i fosfora urinom, osteokalcin i serum-
ski amino terminalni propeptid prokolagena tipa I (P1NP).
Rezultati. U poreĀenju sa kontrolnom grupom eksperi-
mentalne životinje u grupi P imale su snižen jonizovan kal-
cijum u serumu (0,5  ±  0,2 vs  1,12 ± 0,04  mmol/L;
p  <  0,001), povišene fosfate u serumu (2,42  ±  0,46 vs
2,05 ± 0,2mmol/L; p < 0,05), poveýano 24-ÿasovno izluÿi-
vanje kalcijuma urinom (3,90  ±  0,46 vs  3,05 ± 0,58
mmol/24 h; p  < 0,01) i znaÿajno povišen P1NP
(489,22 ± 46,77 vs 361,9 ± 53,01 pg/mL; p < 0,001). Zna-
ÿajan pad P1NP zabeležen je u eksperimentalnoj grupi M3 u
poreĀenju sa kontrolnom grupom. Prolongirana medika-
mentna hiperprolaktinemija u grupi M6 dovela je do porasta
jonizovanog kalcijuma u serumu (1,21  ±  0,03 vs
1,15 ± 0,02mmol/L; p < 0,001), pada fosfata (1,70 ± 0,13 vsStrana 560 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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1,89 ± 0,32  mmol/L;  p  <  0,001) i sniženja koncentracije
osteokalcina i P1NP. Zakljuÿak. Fiziološka hiperprolakti-
nemija u manjoj meri utiÿe na koštani metabolizam nego
medikamentna hiperprolaktinemija. Hroniÿna medikament-
na hiperprolaktinemija dovodi do pada koncentracije P1NP,
što je odraz snižene koštane formacije. Rutinsko odreĀiva-
nje biohemijskih markera koštanog metabolizma u prolongi-
ranoj medikamentnoj hiperprolaktinemiji pruža moguýnost
ranije dijagnoze poremeýaja koštanog metabolizma.
Kljuÿne reÿi:
hiperprolaktinemije; trudnoýa; sulpirid; pacovi;
osteogeneza; biološki pokazatelji; kalcijum; fosfor;
osteokalcin.
Introduction
Hyperprolactinemia (HP) is a common hypothalamic-
pituitary axis disorder. This “abnormal laboratory value” may
be caused by any process interfering with dopamine synthesis,
its transport to the pituitary gland or its action on lactotroph do-
pamine receptors 
1. Considering the complexity of various eti-
ologies, HP could be divided into 4 categories: physiological,
pathological, medicamentous and functional HP.
The most frequent clinical symptoms of HP, regardless
of its origin, are galactorrhea, oligo- or amenorrhea and ste-
rility in women and impotence, libido loss and gynecomastia
in men. In last few decades, there is growing evidence of de-
creased bone mineral density (BMD) and increased activity
of bone turnover markers caused by HP. Prolactin (PRL)-
secreting pituitary tumors in people 
2–6 and rats 
7 are associ-
ated with osteopenia. Antipsychotic-induced HP can cause
osteoporosis and increased risk of hip fracture 
8–10. Preg-
nancy and prolonged lactation, conditions with physiological
HP, can lead to a significant bone loss 
11–13. Although rapid
mineralizing neonatal skeleton (during pregnancy) and
higher calcium demand for milk production (during lacta-
tion) places significant stress on maternal calcium homeosta-
sis, bone loss is usually recovered after weaning 
14–16. Lon-
gidutinal studies have shown that there is no detrimental ef-
fect of parity and prolonged breast-feeding on long-term
bone health 
17, 18.
Although physiological and medicamentous HP have
different final effects on skeletal system, there is a lack of
data regarding the effects of PRL on calcium metabolism and
bone turnover in HP of various origins.
The aim of this experimental study was: 1) to determine
if there was a difference in calcium metabolism during preg-
nancy (physiological HP) and in sulpirid-induced HP
(medicamentous HP); 2) to compare the influence of
medicamentous and physiological HP on bone turnover
markers; 3) and to reveal a possible effect of prolonged
medicamentous HP on calcium metabolism and bone turn-
over markers.
Methods
Animals
Pregnant and age matched nulliparous Wistar female
rats (18 weeks old) were obtained from the Animal Labora-
tory Centre Torlak, Institute for Medical Research, Military
Medical Academy, Belgrade, Serbia. Experimental study
was conducted in Biomedical Research Center, Medical Fac-
ulty, University of Niš, Serbia. The weight of experimental
animals ranged 290–340 g. They were housed under a
12 : 12 h light-dark cycle (lights on at 06 h) and fed standard
chow and water. Room temperature was 23–25°C with aver-
age humidity of 50–60%. The study was approved by the
Ethical Committee of the Medical Faculty, University of Niš,
Serbia.
Experimental design
Experimental animals were divided into the following
groups: 9 rats, 3 week pregnant (P – physiological HP during
pregnancy; gestation period in Wistar rats 19–22 days); 10
rats with intramuscularly administrated sulpirid (10 mg/kg)
twice daily for 3 weeks (M3 – medicamentous HP); 10 rats
with intramuscularly administrated sulpirid (10 mg/kg) twice
daily for 6 weeks (M6 – medicamentous HP). Since bone
growth and calcium accretion are normally age dependent,
we used age matched nulliparous rats as control groups: 10
rats, 18 weeks old (C1), and 7 rats, 24 weeks old (C2). All
rats in each group (pregnant, medicamentous treated and
controls) were sacrificed on the same day.
Laboratory investigations
In order to confirm HP serum PRL levels were meas-
ured in all experimental groups and compared with controls.
PRL concentration was measured using enzyme-linked im-
munosorbent assay kit for PRL. The kit is a sandwich en-
zyme immunoassay for in vitro quantitative measurement of
PRL in rat serum, plasma and other biological fluids (manu-
factured by Uscnk, Life Science Inc.).
All experimental animals were analyzed for serum ion-
ized calcium and urinary calcium, inorganic phosphorus and
urinary phosphate. All rats, in each group, were kept in sin-
gle rat metabolic cages, 24 h before they were sacrificed, in
order to collect 24 h urine for calciuresis and phosphorus di-
uresis. Rats were anesthetized with intramuscular injection of
10% ketamine hydrochloride (0.3 mL per animal). Blood
samples untill exsanguination  were taken by punction of left
myocardial ventricle through midline thoracoabdominal inci-
sion. Mineral assays were done by the following methods:
serum ionized calcium by potentiometric method; urine cal-
cium by photometric colour test (Beckman Coulter, OLYM-
PUS analyzer); serum and urine phosphate concentration by
photometric UV test (Beckman Coulter, OLYMPUS ana-
lyzer); The bone turnover markers studied were: osteocalcin
(OC) and serum procollagen type 1 N-terminal propeptide
(P1NP). The methods used for bone turnover markers were:
OC by electrochemiluminescence immunoassay (N-MID
Osteocalcin, Cobas, Roche) and P1NP was measured using
enzyme-linked immunosorbent assay kit for P1NP (Uscnk,
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Statistical analysis
Data were analyzed using SPSS (version 15.0). Con-
tinuous (measurable) parameters were presented with mean
values (ʉ) and standard deviation (SD), median (md), maxi-
mum (max) and minimum (min) values. The Shapiro-Wilk test
was used to determine normality of parameters distribution.
Differences were tested by Student's t-test for independent
samples if the distribution of parameters was normal and
Mann-Whitney U-test was used if parameters distribution was
deviated. We used Student's t-test for dependent samples
(normal distribution) and Wilcoxon test (deviated distribution)
to test statistical significance between continuous parameter
values at the beginning and the end of the study.
Results
Changes in prolactin concentration, calcium
metabolism and bone turnover markers in
physiological hyperprolactinemia
PRL concentrations were significantly higher during the
third week of pregnancy (P), compared with C1 (181.80 ± 29.65
vs 105.38 ± 28.34 pg/mL; p < 0.001) (Table 1).
OC concentrations were significantly lower during
pregnancy compared to C1 (9.01  ±  1.09 ng/mL vs
17.50 ± 2.76 ng/mL, p < 0.001) (Table 1).
P1NP concentrations were significantly higher in
physiological HP (P) in comparison to that in the C1 group
(489.22 ± 46.77  pg/mL  vs  361 ± 53.01  pg/mL,  p < 0.001)
(Table 1).
Serum ionized calcium concentrations were signifi-
cantly decreased in pregnancy (0.5  ±  0.2 mmol/L vs
1.12 ± 0.04 mmol/L, p < 0.001) followed by significantly in-
creased phosphorus compared to C1 (2.42 ± 0.46 mmol/L vs
2.05 ± 0.19 mmol/L; p < 0.05) (Table 2).
Urinary calcium and phosphorus excretion (measured
as daily total calcium and daily phosphorus excretion) sig-
nificantly increased during pregnancy compared to the con-
trol group (urinary calcium 3.90  ±  0.46 mmoL/24 h vs
3.05 ± 0.58  mmoL/24  h;  p < 0.01;  urinary  phosphorus
141.15 ± 20.65  mmoL/24  h  vs  45.54 ± 7.99  mmoL/24  h,
p < 0.001) (Table 2).
Changes in prolactin concentration, calcium
metabolism and bone turnover markers in
medicamentous hyperprolactinemia
Significantly increased PRL levels in sulpirid-treated
rats, compared to age matched controls, confirmed the state
of medicamentous HP (M3: 182.03  ±  57.80 vs
105.38 ± 28.34  pg/mL;  p < 0.001;  M6:  148.92 ± 20.46  vs
112.01 ± 11.92 pg/mL, p < 0.001). Even though lower PRL
concentration were verified in M6 in comparison with M3,
decrease was not significant (148.92 ± 20.46 vs 182.03 ± 57.80
pg/mL, p > 0.05).
In medicamentous HP (M3), serum calcium levels were
higher, with no significant difference compared to C1
(1.15 r 0.04 vs 1.12 r 0.04 mmol/L) but serum calcium levels
in physiological HP were significantly decreased in comparison
with M3 (0.5 ± 0.2 vs 1.15 r 0.04 mmol/L, p < 0.001). Phospho-
rus concentrations were not significantly changed during 3
weeks of medicamentous HP compared to C1 (2.14 ± 0.48 vs
2.05 ± 0.19 mmol/L, p > 0.05). Even though lower phosphorus
concentration were verified in comparison with pregnant rats, a
decrease was not significant (2.14  ±  0.48 vs  2.42 ± 0.46
Table 1
Concentration of prolactin, osteocalcin and P1NP in experimental groups
Prolactin (pg/mL) Osteocalcin (ng/mL) P1NP Experimental groups ʉ ± SD ʉ ± SD ʉ ± SD
C1 105.38 ± 28.34 17.5 ± 2.76 361.90 ± 53.01
P 181.8 ± 29.65 9.01 ± 1.09 489.22 ± 46.77
M3 182.03 ± 57.8 15.28 ± 2.51 309.60 ± 36.74
M6 148.92 ± 20.46 13.55 ± 3.42 291.70 ± 71.03
C2 112.01 ± 11.92 16.18 ± 2.0 314.86 ± 50.99
< 0.001 (P : C1) < 0.001 (P : C1)
< 0.001 (M3 : C1) < 0.05 (M3 : C1) p
< 0.001 (M6 : C2) < 0.001 (M3 : P)
Experimental groups: P –  physiological hyperprolactinemia (HP) during pregnancy; M3 – medicamentous HP with a 3-week duration;  M6 – medicamentous
HP with a 6-week duration; C1 – control group age matched with P and M3; C2 – control group age matched with M6; ʉ ± SD – mean value; SD – standard de-
viation.
Table 2
Calcium and posphorous serum concentrations and 24-h urine exeretion values
C1 P M3 M6 C2 Parameter (n = 10) (n = 9) (n = 10) (n = 10) (n = 7)
Serum ionized calcium (mmol/L), ʉ ± SD 1.12 ± 0.04 0.50 ± 0.20
‡ 1.15 ± 0.04 1.21 ± 0.03
‡ 1.15 ± 0.02
Serum phosphorous (mmol/L), ʉ ± SD 2.05 ± 0.19 2.42 ± 0.46* 2.14 ± 0.48 1.70 ± 0.13 1.89 ± 0.32
Urine calcium excretion (mmol/24 h), ʉ ± SD 3.05 ± 0.58 3.90 ± 0.46
† 4.31 ± 1.11
† 2.88 ± 0.60 3.37 ± 0.87
Urine phosphorous (mmol/24 h) excretion (ʉ ± SD) 45.54 ± 7.99 141.15 ±20.65
‡ 50.58 ± 9.77 53.93 ± 14.05 55.03 ± 20.37
*p < 0.05 (P vs C1); 
†p < 0.01 (P vs C1; M3 vs C1, M6); 
‡p < 0.001
P, M3, M6, C1, C2 (for explantation see under Table 1).Strana 562 VOJNOSANITETSKI PREGLED Volumen 71, Broj 6
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mmol/L). With prolongation of medicamentous HP (M6) cal-
cium concentrations continued to rise and serum phosphorus
levels to fall. After 6 weeks of sulpirid provoked HP, serum cal-
cium concentrations were significantly increased in comparison
with C2 (1.21  r 0.03  mmol/L  vs 1.15  r 0.02  mmol/L,
p < 0.001). There was no significant difference in serum phos-
phorus concentrations with a prolongation of sulpirid treatment
(1.70 ± 0.13 mmol/L vs 1.89 ± 0.32 mmol/L, p > 0.05).
In M3 rats calciuresis was significantly increased com-
pared to the control group (4.31  ±  1.11 mmoL/24 h vs
3.05 ± 0.58 mmoL/24 h; p < 0.01) while phosphorus diuresis
was not significantly changed (50.58  ±  9.77 mmoL/24 h vs
45.54 ± 7.99 mmoL/24 h, p > 0.05).
With longer duration of medicamentous HP (M6) there
were no significant changes in urinary calcium and phospho-
rus excretion compared to C2 (calciuresis: 2.88  ±  0.6
mmoL/24 h vs 3.37 ± 0.87 mmoL/24 h; phosphorus diuresis:
53.93 ± 14.05 mmoL/24 h vs 55.03 ± 20.37 mmoL/24 h).
OC concentrations were decreased in sulpirid-treated rats
compared to age matched control groups (M3: 15.28  ±  2.51
ng/mL  vs  17.50 ± 2.76  ng/mL;  M6:  13.55 ± 3.42  ng/mL  vs
16.18 ± 2.0 ng/mL) but without statistical significancy.
P1NP concentration in M3 compared to C1 was signifi-
cantly  decreased  (309.60 pg/mL   ± 36.74  vs  361.90 ± 53.01
pg/mL, p < 0.05) and even more in comparison with physio-
logical HP (309.60 ± 36.74 pg/mL vs 489.22 ± 46.77 pg/mL;
p < 0.001). Although the tendency of further P1NP decrease
was noticed with longer duration of medicamentous HP, no
significant difference was verified (291.70 ± 71.03 pg/mL, vs
314.86 ± 50.99 pg/mL, p > 0.05).
Discussion
Our study results confirmed the expected PRL increase
during pregnancy. The results of mineral analyses and bone
turnover markers conducted in this experimental group could
be considered as representative for physiological HP.
Calcium homeostasis during pregnancy is changed due
to elevated fetus demand for calcium and maternal adapta-
tions. Adaptation mechanisms include increase in intestinal
calcium absorption, decrease in urinary calcium excretion or
mobilization of maternal bone mineral.
A decrease in total serum calcium concentration during
pregnancy has already been reported 
19, 20 and usually con-
sidered as a consequence of hemodilution and decreased se-
rum albumin 
19, 21, 22. In order to avoid low calcium concen-
tration due to dilutional effect, we measured serum ionized
calcium level. Our study results confirmed a significant de-
crease in ionized calcium, which is in the contrast with pre-
viously reported results of unchanged ionized calcium
throughout gestation 
23, 24 and more consistent with data from
several animal models, reporting fall of ionized calcium in
late pregnancy 
25, 26. Rapid fetus growing in late pregnancy
may exceed the maternal capacity to maintain a normal se-
rum calcium level and result in decreased ionized calcium.
Inorganic phosphorus is very often considered to be a pas-
sive companion of calcium fluxes. Studies which evaluate phos-
phate balance during physiological HP (as pregnancy) are less
common than calcium studies. Serum phosphate levels are usu-
ally reported as normal throughout pregnancy in humans and
animals 
19, 21. Our study results showed significantly increased
serum phosphorus during pregnancy. It is consistent with de-
creased serum ionized calcium in our experimental study, in-
creased parathyroid hormone during rat pregnancy, reported in
previous animal models 
21 and a fact that dietary phosphorus is
absorbed almost twice as efficiently as dietary calcium 
27.
The increase of urinary calcium excretion during preg-
nancy is consistent with previous reports 
19, 20. It is consid-
ered as a consequence of increased calcium absorption and
elevation in glomerular filtration rate (GFR) during preg-
nancy, which together exceed the reabsorptive capacity of
the kidney 
19–21.
Changes in urinary phosphorus excretion, during preg-
nancy, could be also due to increased dietary intake in late
pregnancy, increased absorption and increased GFR during
pregnancy.
OC fulfils all three of the following criteria for reliable
bone turnover marker: it is osteoblast-produced protein, its
increase correlates with increased bone formation, and it has
fast response to changes in skeletal homeostasis. A decline in
serum OC during pregnancy, in this study is consistent with
the findings of previous reports 
19, 20, 28, 29. Decreased OC in
pregnancy may be related to hemodilution, fetal contribu-
tion 
20, increased renal degradation secondary to increased
GFR 
29 or lacking of normal values during pregnancy 
22.
P1NP together with carboxy terminal propeptide
(P1CP) are a part of the process in which type I procollagen
is transformed into type I collagen. Since type I collagen
constitutes 90% of bone proteins, it may be considered as
very valuable and precise marker of bone formation. Our
study results are consistent with limited, previously reported
data, showing low P1CP and P1NP concentration in the first
trimester 
28, 30 with the tendency to rise above normal in the
late pregnancy 
30, 31. Higher osteoblastic activity, in physio-
logical HP, could explain faster recovery of bone loss after
pregnancy and lactation.
Increased PRL levels in sulpirid-treated rats were con-
firmed in our study. Therefore, the results of mineral analy-
ses and bone turnover markers, conducted in these experi-
mental groups, could be considered as representative for
medicamentous HP. With sulpirid treatment prolongation
slightly decreased PRL concentrations were verified. Data
from the literature usually cover the issue of different sul-
piride effects, according to the low or high dosages 
32. Lower
concentration of dopamine antagonist (sulpiride) can block
presynaptic dopamine (D) 2 receptors, leading to decreased
dopamine synthesis and release. Lactotrophs are released of
dopamine inhibition and hyperprolactinemia occurs. Higher
sulpiride concentrations are needed to block postsynaptic D2
receptors 
33. There are no literature data showing different ef-
fect of sulpiride with longer treatment duration. A possible
explanation for decreased PRL concentration with prolonga-
tion of sulpiride treatment could be up-regulation of D2 re-
ceptors in lactotrophs after longer blocking sulpiride effect or
postreceptors downstream of cAMP/calcium signalling
which is necessary for PRL release 
34.Volumen 71, Broj 6 VOJNOSANITETSKI PREGLED Strana 563
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Studies conducted to reveal a connection between
medicamentous HP and skeletal system are often based on pa-
rameters of bone mineral density and biochemical turnover
markers. There are less available data about HP influence on
calcium and phosphorus levels. Our study results, showing no
significant changes in serum ionized calcium and phosphorus,
during a 3-week sulpirid-provoked HP, are consistent with
limited previously reported data 
35–37. Even though there are
growing evidences that prolonged medicamentous HP can lead
to decreased bone mineral density 
8–10, 36, there are still missing
data about calcium and phosphorus changes during those con-
ditions. Our study results revealed a significant calcium in-
crease and phosphorus decrease during longer medicamentous
HP. Hypercalcemia in prolonged medicamentous HP could be
a result of increased calcium absorption in upper intestine (ab-
sorptive hypercalcemia), increased net bone resorption (re-
modelling hypercalcemia) or increased tubular calcium reab-
sorption (tubular reabsorptive hypercalcemia). In last decade,
many experimental studies confirmed very important and di-
rect PRL role in regulating intestinal calcium absorption 
38–41.
All of these studies are based on physiological HP. There are
no literature data showing that medicamentous HP also leads
to increased intestinal calcium absorption. The findings of
PRL receptor mRNA expression in osteosarcoma cell lines 
42,
cultured calvaria osteoblasts 
43 and in tibia, femur and verte-
brae in normal adult rats 
44 suggested bones as possible direct
targets of PRL. It is still uncertain whether hypercalcemia in
prolonged medicamentous HP could be considered as a conse-
quence of direct PRL influence on bones.
Renal tubular dysfunction resulting in excess calcium
loss, caused by sulpirid is not so far reported. A significant
fall of urinary calcium excretion in prolonged medicamen-
tous HP was not previously reported, to our knowledge, and
could be a result of some still unknown mechanisms,
switched on to prevent further calcium loss.
Different studies conducted in women with major de-
pressive disorder, with or without borderline personality dis-
order, before psychotropic medication, or treated with anti-
depressant, found increased OC 
35, 45, 46. Our study results,
presenting lower OC, but still in normal referent rang, are
more consistent with data provided in schizophrenic patients
with antipsychotic treatment 
36, 47.
There are no previously reported data, to our knowl-
edge, about changes in P1NP in medicamentous HP. Our re-
sults, for the first time show statistical significant decrease of
this osteoblastic marker in sulpirid-induced HP. Prolonged
medicamentous HP leads to further fall of P1NP, reflecting
poor osteoblastic activity.
Even though OC and P1NP are bone formation markers
their serum levels reflect different aspects of osteoblastic ac-
tivity. Osteocalcin is mostly produced during the mineraliza-
tion phase, while procollagen peptides are mostly produced
by proliferating osteoblasts 
47.
Limitation of this study is a lack of biochemical mark-
ers of bone resorption. Comparison of bone resorp-
tion/formation rates could also be very important data about
bone remodelling in physiological and medicamentous hy-
perprolactinemia.
Conclusion
We demonstrated herein that ionized calcium concen-
trations were significantly different in physiological and
medicamentous hyperprolactinemia (decreased in late preg-
nancy and increased in sulpirid-induced hyperprolactinemia).
Quite opposite influence of physiological and medicamen-
tous hyperprolactinemia on bone formation marker procolla-
gen type 1 N-terminal propeptide, revealed an increased os-
teoblastic activity in pregnancy and decreased bone forma-
tion in sulpirid-provoked hyperprolactinemia. These results
provide a possible explanation why pregnancy does not de-
termine such harmful effect on bone metabolism, while
medicamentous hyperprolactinemia leads to decreased bone
mineral density. The present experimental data of further
procollagen type 1 N-terminal propeptide decrease in pro-
longed medicamentous hyperprolactinemia, provide infor-
mation on dynamic, time-dependent and origin-dependent
osteoregulatory roles of prolactin.
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